BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  BioTelemetry, Inc. to Release Third Quarter 2017 Earnings Results on November 7, 2017

  The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com.

  October 31, 2017

   · 

  1 min read
• Business

  Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2017 Earnings

  A replay of the call will be available on Intellia’s website, beginning on October 31 at 11:00am EDT, 2017.

  October 31, 2017

   · 

  1 min read
• Deals

  Ablynx Closes on Underwriters’ Option to Purchase $30M of Additional Shares in the U.S. Initial Public Offering

  The underwriters exercised their option to purchase additional ADSs, in full, on October 26, 2017.

  October 31, 2017

   · 

  6 min read
• Business

  OrthoPediatrics to Report Third Quarter 2017 Financial Results on November 8, 2017

  OrthoPediatrics will host a conference call on Thursday, November 9, 2017 at 8:00 a.m. ET to discuss the results.

  October 31, 2017

   · 

  1 min read
• Business

  Promore Pharma Signs Agreement With CRO PCG Clinical Services

  Promore Pharma has signed an agreement with CRO PCG Clinical Services regarding the management of Promore Pharma’s LL-37 Phase IIb trial in patients with venous leg ulcers (VLU).

  October 31, 2017

   · 

  4 min read
• Business

  Oxford Immunotec Reports Third Quarter 2017 Financial Results

  Revenue for the third quarter of 2017 was $30.4 million, representing 17% growth over third quarter 2016 revenue of $26.1 million.

  October 31, 2017

   · 

  12 min read
• 

  Drug Development

  Sanofi: Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in a Phase III Study of People With Severe Steroid-Dependent Asthma

  Dupilumab added to standard therapies significantly reduced the use of maintenance oral corticosteroids (OCS) by 70% on average.

  October 31, 2017

   · 

  18 min read
• Business

  OMRON Increases Net Earnings 91.2% to JPY30.3 Billion on Solid Gains in Core Industrial Automation Business

  Net sales for the period increased 10.5%, to JPY410.5 billion.

  October 31, 2017

   · 

  3 min read
• Orexo Issues Bonds of SEK 325 Million and Confirms Fulfilment of Condition Under Notice of Early Redemption

  Orexo has issued a four-year senior unsecured bond loan in an amount of SEK 325 million, within a framework amount of SEK 500 million, due in November 2021.

  October 31, 2017

   · 

  2 min read
• Business

  Acorda Provides Financial and Pipeline Update for Third Quarter 2017

  AMPYRA (dalfampridine) Extended Release Tablets, 10 mg - For the quarter ended September 30, 2017, the Company reported AMPYRA net revenue of $132.6 million compared to $128.8 million for the same quarter in 2016.

  October 31, 2017

   · 

  14 min read